These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 15364753)

  • 1. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
    Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
    J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
    Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
    Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
    Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
    Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging non-small cell lung cancer with whole-body PET.
    Marom EM; McAdams HP; Erasmus JJ; Goodman PC; Culhane DK; Coleman RE; Herndon JE; Patz EF
    Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.
    Ose N; Sawabata N; Minami M; Inoue M; Shintani Y; Kadota Y; Okumura M
    Eur J Cardiothorac Surg; 2012 Jul; 42(1):89-92. PubMed ID: 22290887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
    Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
    Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
    Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
    Yi CA; Lee KS; Lee HY; Kim S; Kwon OJ; Kim H; Choi JY; Kim BT; Hwang HS; Shim YM
    Cancer; 2013 May; 119(10):1784-91. PubMed ID: 23423920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
    Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA
    Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
    Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
    Lardinois D; Weder W; Roudas M; von Schulthess GK; Tutic M; Moch H; Stahel RA; Steinert HC
    J Clin Oncol; 2005 Oct; 23(28):6846-53. PubMed ID: 16192576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
    Truong MT; Viswanathan C; Erasmus JJ
    J Thorac Imaging; 2011 May; 26(2):132-46. PubMed ID: 21508735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
    Cheran SK; Herndon JE; Patz EF
    Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of FDG PET in the management of NSCLC.
    Ukena D; Hellwig D
    Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer.
    Gayed I; Vu T; Johnson M; Macapinlac H; Podoloff D
    Mol Imaging Biol; 2003; 5(1):26-31. PubMed ID: 14499159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.